Towards host-directed therapies for tuberculosis
7 August 2015
Abstract: The treatment of tuberculosis is based on combinations of drugs that directly target Mycobacterium tuberculosis. A new global initiative is now focusing on a complementary approach of developing adjunct host-directed therapies.
Zumla A1, Chakaya J2, Hoelscher M3, Ntoumi F4, Rustomjee R5, Vilaplana C6, Yeboah-Manu D7, Rasolof V8, Munderi P9, Singh N10, Aklillu E11, Padayatchi N12, Macete E13, Kapata N14, Mulenga M15, Kibiki G16, Mfinanga S17, Nyirenda T18, Maboko L19, Garcia-Basteiro A13, Rakotosamimanana N8, Bates M14, Mwaba P14, Reither K20, Gagneux S20, Edwards S21, Mfinanga E22, Abdulla S23, Cardona PJ6, Russell JB24, Gant V25, Noursadeghi M1, Elkington P26, Bonnet M27, Menendez C28, Dieye TN29, Diarra B30, Maiga A30, Aseffa A31, Parida S32, Wejse C33, Petersen E33, Kaleebu P9, Oliver M34, Craig G35, Corrah T36, Tientcheu L37, Antonio M37, Rao M32, McHugh TD38, Sheikh A39, Ippolito G40, Ramjee G41, Kaufmann SH42, Churchyard G43, Steyn A44, Grobusch M45, Sanne I46, Martinson N47, Madansein R48, Wilkinson RJ49, Mayosi B50, Schito M51, Wallis RS43, Maeurer M32.